BioProducts Laboratory

BioProducts Laboratory (BPL) is a leading global pharmaceutical company specializing in the development and manufacture of plasma-derived therapies. Headquartered in Elstree, United Kingdom, the company processes human plasma to produce essential treatments for rare and serious medical conditions in the fields of immunology, hematology, and critical care. BPL's product portfolio includes high-quality biologics such as Coagadex for Factor X deficiency, Gammaplex for primary immunodeficiencies, and various albumin and coagulation factor products. The company also operates an extensive network of plasma collection centers in the United States through its subsidiary, BPL Plasma. In 2022, BPL was acquired by Kedrion Biopharma, creating a major international player in the plasma protein industry and expanding its global reach to over 60 countries.